Literature DB >> 15786960

[The antiarrhythmic effect of (-)-U-50,488 in rats with acute ischemia and reperfusion of heart is mediated by kappa1-opioid receptor activation].

L N Maslov, A Iu Lishmanov, N V Solenkova, E V Budankova, T M Wong, W C Chang, L X Bray.   

Abstract

Pretreatment with a selective kappa1 opioid receptor (OR) agonist (-)-U-50,488 (1 mg/kg, i.v.) prevented the development of arrhythmias induced by occlusion (10 min) and reperfusion (10 min) in ketamine anesthetized rats, while the treatment with a less active enantiomer (+)-U-50,488 in the same dose produced no such effects. Preliminary intravenous administration of a selective kappa1 OR antagonist norbinaltorphimine (9 mg/kg) fully abolished the antiarrhythmic effect of (-)-U-50,488, while the kappa2 OR antagonist quadazocine (3 mg/kg) did not eliminate this effect. The injections of norbinaltorphimine or quadazocine alone did not influence the incidence of model arrhythmias caused by the occlusion and reperfusion. It was concluded that kappa1 OR stimulation favors an increase in cardiac tolerance to the arrhythmogenic action of occlusion and reperfusion.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15786960

Source DB:  PubMed          Journal:  Eksp Klin Farmakol        ISSN: 0869-2092


  2 in total

1.  Cardioprotective and antiarrhythmic effect of U50,488H in ischemia/reperfusion rat heart.

Authors:  Liang Cheng; Sai Ma; Long-Xiao Wei; Hai-Tao Guo; Lu-Yu Huang; Hui Bi; Rong Fan; Juan Li; Ya-Li Liu; Yue-Min Wang; Xin Sun; Quan-Yu Zhang; Shi-Qiang Yu; Ding-Hua Yi; Xin-Liang Ma; Jian-Ming Pei
Journal:  Heart Vessels       Date:  2007-09-20       Impact factor: 2.037

Review 2.  Prospects for Creation of Cardioprotective and Antiarrhythmic Drugs Based on Opioid Receptor Agonists.

Authors:  Leonid N Maslov; Igor Khaliulin; Peter R Oeltgen; Natalia V Naryzhnaya; Jian-Ming Pei; Stephen A Brown; Yury B Lishmanov; James M Downey
Journal:  Med Res Rev       Date:  2016-05-16       Impact factor: 12.944

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.